Baxter International Inc. (BAX)
Does Baxter Stock Offer Any Room For Growth?
Baxter stock (NYSE: BAX), a healthcare company, currently trades at $38 per share, more than 50% lower than the level seen in February 2022. BAX stock has fared worse than its peer – Becton, Dickinson & Company stock, down 7% over this period.
Baxter Shares May Gain on the Launch of Its Latest Vest APX System
BAX launches its next-generation airway clearance system, The Vest APX System, for chronic lung conditions.
4 Medical Product Stocks to Buy From a Prospective Industry
Ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, BAX, HAE and PAHC are well-poised to gain from the favorable factors.
5 Incredible Healthcare High-Yield Blue-Chip Bargain Buys For 2025
Healthcare is undervalued despite being the top sector for earnings growth, making it an attractive investment with solid fundamentals and the potential for explosive returns in 2025. Investing in healthcare ETFs or individual undervalued healthcare stocks can capitalize on the sector's recovery and expected double-digit growth through 2026. Screening for blue-chip healthcare stocks with solid fundamentals and fair valuations can yield superior returns, including these five coiled spring blue chips.
Baxter (BAX) Upgraded to Buy: Here's Why
Baxter (BAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BAX vs. PODD: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Baxter International (BAX) and Insulet (PODD). But which of these two stocks is more attractive to value investors?
Is Baxter International (BAX) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Baxter International (BAX) Recently Broke Out Above the 200-Day Moving Average
From a technical perspective, Baxter International (BAX) is looking like an interesting pick, as it just reached a key level of support. BAX recently overtook the 200-day moving average, and this suggests a long-term bullish trend.
10 Great Dividend Stocks For The Next 10 Years
The focus of this article is to provide a select list of 10 dividend stocks that, in our view, are currently undervalued and should provide an average of 4.5% plus yield for the foreseeable future. We use a simple and easy-to-implement filtering method to narrow down our list to probable candidates. In our view, these dividend stocks will provide sustainable yields with decent dividend growth that will likely meet and exceed the rate of inflation.
Baxter's (BAX) Vantive Divestiture to Aid Its Operational Sales
Baxter (BAX) announces the divestiture of its Kidney Care segment, Vantive, to a global investment firm Carlyle.
Why Baxter International (BAX) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Baxter Stock Falls After it Unloads Kidney Care Division in $3.8B Deal
Shares of Baxter International (BAX) fell Tuesday after the company said it would sell its kidney treatment division to The Carlyle Group (CG) for $3.8 billion in cash.
